slideshow 1

Acpharis CEO and CSO Speak on Using Computational Solvent Mapping to Drive Hits into Leads

At two conferences today, GTC Bio's Drug Discovery and Medicinal Chemistry in San Diego and CHI's Structure-Based Drug Discovery in Cambridge, Acpahris's CEO and CSO described the use of computational solvent mapping to guide the development of fragment hits into leads.

Schrödinger Licenses PIPER from Acpharis

Acpharis has granted a license to Schrödinger for the use of the PIPER protein-protein docking in their new biologics program BioLuminate. PIPER is a state of the art protein-protein docking program licensed to Acpharis by Boston University.

Acpharis CSO Speaks at Drug Discovery Chemistry Conference

Sandor Vajda, Acpharis CSO, spoke today at CHI's Drug Discovery Chemistry Conference in San Diego on the druggability of protein-protein interaction targets. By applying computational solvent mapping to these targets, one is able to find energetically favorable sites for the binding of fragment-sized molecules. The diversity of fragments that bind into these sites is a predictor of druggability, providing early information on the ability to drug members of this frequently intractable class of targets.